Skip to search formSkip to main contentSkip to account menu
  • Publications
  • Influence
Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial
View on Elsevier
Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or…
View on PubMed
Prognostic factors for patients with hepatic metastases from breast cancer
TLDR
Factors that significantly predicted a poor prognosis on univariate analysis included symptomatic liver disease, deranged liver function tests, the presence of ascites, histological grade 3 disease at primary presentation, advanced age, oestrogen receptor (ER) negative tumours, carcinoembryonic antigen of over 1000 ng ml−1 and multiple vs single liver metastases.
View on Nature
Bone metastases from breast carcinoma: histopathological – radiological correlations and prognostic features
TLDR
A multivariate analysis found that metastasis-free interval, additional sites of metastatic disease other than bone, ER status and serological tumour marker levels all independently contributed to survival from time of presentation with bone metastases.
View on Springer
CONCEPTS OF SEROMA FORMATION AND PREVENTION IN BREAST CANCER SURGERY
TLDR
The aim of this paper is to review the concepts of pathophysiology of seroma formation following mastectomy and breast‐conserving surgery for cancer and the various techniques in practice to reduce its incidence and treatment.
View on Wiley
Brain metastases from breast cancer: identification of a high-risk group.
View on PubMed
Neoadjuvant chemotherapy for locally advanced breast cancer: a review of the literature and future directions.
View on PubMed
Tumour marker measurements in the diagnosis and monitoring of breast cancer.
TLDR
Intensive laboratory work is being carried out to optimize the use of blood markers in advanced disease as well as to exploit their use in screening and diagnosis of early primary breast cancer.
View on PubMed
Clinical and endocrine data for goserelin plus anastrozole as second-line endocrine therapy for premenopausal advanced breast cancer
TLDR
The combined use of goserelin and anastrozole as second-line endocrine therapy produces a significant clinical response of worthwhile duration, with demonstrable endocrine changes, in premenopausal women with advanced breast cancer, and offers them another therapeutic option.
View on Springer
Subcutaneous mastectomy for primary breast cancer and ductal carcinoma in situ.
View on PubMed
...
...
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License